Dr. Reddy’s Pumps Complex Generics Play With Teva Deal
This article was originally published in PharmAsia News
Dr. Reddy's is acquiring a basket of ANDAs from Teva as it increasingly leans towards developing and building a portfolio of complex and limited competition generics in the US and hopes to become "more relevant" there.
You may also be interested in...
Dr. Reddy’s Laboratories (DRL) has reported a slump in profits for the first quarter, dented by a decline in volume growth and pricing pressure in the US as well as a loss of business in Venezuela. While the firm's long term story appears intact, resolution of compliance issues at its Indian sites and product flows in the US and other markets (DRL expects to participate in a Russian tender for rituximab) could lift investor sentiment significantly.
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.